Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer

Daisuke Takahari; Yasuhiro Shimada; Shigeyuki Takeshita; Hitoshi Nishitani; Atsuo Takashima; Natsuko Okita; Yoshinori Hirashima; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Kuniaki Shirao

首页> 外文期刊>Gastric Cancer >Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer

【24h】

Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer

机译：S-1单药治疗晚期胃癌失败后，伊立替康联合顺铂二线化疗

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

For advanced gastric cancer (AGC), second-line chemotherapy after the failure of S-1 has not yet been established. The present study aimed to retrospectively evaluate the efficacy and safety of irinotecan plus cisplatin (IP) therapy after the failure of S-1 in patients with AGC.

机译：对于晚期胃癌（AGC），尚未确定S-1失败后的二线化疗。本研究旨在回顾性评估AGC患者S-1失败后伊立替康联合顺铂（IP）治疗的疗效和安全性。

著录项

来源
《Gastric Cancer》 |2010年第3期|p.186-190|共5页
作者
Daisuke Takahari; Yasuhiro Shimada; Shigeyuki Takeshita; Hitoshi Nishitani; Atsuo Takashima; Natsuko Okita; Yoshinori Hirashima; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Kuniaki Shirao;
展开▼
作者单位

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, Japan;

Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo,;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Irinotecan; Cisplatin; Gastric cancer; Second-line chemotherapy; S-1 failure;

机译：伊立替康;顺铂;胃癌;二线化疗;S-1失败;

相似文献

外文文献
中文文献
专利

1. Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer. [J] . Takahari D, Shimada Y, Takeshita S, Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association . 2010,第3期

机译：S-1单一疗法治疗晚期胃癌失败后，用伊立替康加顺铂进行二线化疗。
2. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial [J] . Nishikawa Kazuhiro, Fujitani Kazumasa, Inagaki Hitoshi, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2015,第7期

机译：TRICS试验：二线伊立替康联合顺铂与伊立替康单药治疗在S-1单一疗法难以治疗的晚期胃癌患者中的随机III期试验：TRICS试验
3. A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naive patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial [J] . Nishikawa Kazuhiro, Murotani Kenta, Fujitani Kazumasa, Cancer chemotherapy and pharmacology. . 2019,第5期

机译：单独的二氯丹加铂铂中的二线伊替康患者研究了铂 - 野生患者的胃癌难治对佐剂S-1单一疗法：随机阶段三种特定试验的探索性亚组分析
4. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens [O] . MASARU OBA, KEISHO CHIN, YOSHIMASA KAWAZOE, -1

机译：在基于氟嘧啶的治疗方案失败后二线治疗中伊立替康单药治疗优于伊立替康加顺铂联合治疗的晚期胃癌
7. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial [O] . Nishikawa Kazuhiro, Fujitani Kazumasa, Inagaki Hitoshi, 2015

机译：TRICS试验：二线伊立替康联合顺铂与伊立替康单独治疗晚期难治性S-1晚期胃癌患者的III期随机试验：TRICS试验

Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer

摘要

著录项

相似文献

相关主题

期刊订阅